LYON, France--(BUSINESS WIRE)--iDD biotech today announces the achievement of the first milestone under the agreement signed one year ago with Genmab A/S, a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Genmab has selected iDD biotech’s antibody as a clinical candidate for further development. Under the terms of the agreement, Genmab will pay iDD Biotech a fee of EUR 3.
↧